Four core genes, TREM2, GDF15, TTC39A, and ANXA2, were identified as key to influencing HCC prognosis and therapy responsiveness, especially immune treatment efficacy in NASH-associated HCC. The gene discussed is TTC39A; the disease is metabolic dysfunction-associated steatohepatitis.